Prof. Cesare Sirtori developed a career of Clinical Pharmacologist, having obtained, after  the Medical Degree at the University of Milano (1967), the title of Doctor of Philosophy in Clinical Pharmacology at the University of Kansas, USA. After his return to Italy, in 1972 he started in Milano one of the first Centers for the Study of Metabolic Diseases with  a high atherosclerosis risk. The Center E. Grossi Paoletti, located at the Niguarda Ca' Granda Hospital in Milano, is the world's second  largest Lipid Clinic  and  a  leading  Center for clinical research  in the field of hyperlipoproteinemias, thrombosis and non invasive monitoring of vascular lesions. Is Board  certified  in Cardiology.

Prof. Sirtori has been Ordinary Professor of Chemotherapy at the University of Milano from 1980 to 1988; since 1989 is Ordinary Professor of Clinical Pharmacology in the same University. Has been a Member of the Presidential Board of  the  Italian Society of Pharmacology,  President of the Mediterranean European Dietetic Association, and  President of the Italian Atherosclerosis Society. He has been President  for the 2006 XIV Atherosclerosis Symposium in Rome.

Is the Author of over 500 scientific  publications, more than 300 of which on high standard clinical and biological journals, quoted in  over  10,000 publications. Among the major scientific observations:

• the recognition  of  the first mutant of human apolipoproteins (apo A-IMilano);

• the definition of the clinical activity and mechanism of action of the soybean protein diet in the management of hypercholesterolemia;

• major clinical  observations  on the hypolipidemic/lipoprotein  modifying  activity of olive oil;

• original data on the mechanism of action of numerous hypolipidemic compounds, from fibric acids, to statins,  to probucol;

• long-term of clinical effects and  changes in the glucose tolerance status after n-3 enriched diets.

Finally,  Prof. Sirtori has provided  significant  contributions in the field of clinical pharmacology:   kinetics of antidiabetic biguanides; kinetics and mechanism of action of numerous  compounds (celiprolol, ribavirin, acipimox, etc.) with detection of the first  P-450 polymorphism (now CYP2D6); activity of different  oral contraceptives on the P-450 system, and of hypolipidemic agents on platelet aggregation/fibrinolysis.